

# Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE Trial

Pajon, R. et al.

## Supplement

**Table S1. Baseline and demographics characteristics viral copy analysis population**

Characteristics n (%)	Placebo N=653	mRNA-1273 N=48
Age (y)		
Mean (SD)	48.0 (14.4)	49.5 (14.6)
Median (Min, Max)	48 (18-87)	49 (24-74)
Sex		
Female	324 (49.7)	23 (47.9)
Male	329 (50.3)	25 (52.1)
Race		
White	560 (85.6)	43 (89.6)
Black or African American	30 (4.6)	2 (4.2)
Asian	26 (4.0)	1 (2.1)
American Indian or Alaska Native	4 (0.6)	0
Multiple	8 (1.2)	1 (2.1)
Other	15 (2.3)	1
Not reported or unknown	10 (1.5)	0
Ethnicity		
Hispanic or Latino	150 (22.8)	9 (18.8)
Not Hispanic or Latino	500 (76.8)	39 (81.3)
Not reported or unknown	3 (0.5)	0
Risk Factor for Severe Covid-19 at Screening*		
Chronic lung disease	24 (3.7)	4 (8.3)
Significant cardiac disease	29 (4.5)	3 (6.3)
Severe obesity	65 (9.9)	7 (14.6)
Diabetes	64 (9.8)	3 (6.3)
Liver disease	5 (0.8)	1 (2.1)
HIV	2 (0.3)	0
Body Mass Index, (kg/m <sup>2</sup> )		
n	650	48
Mean (SD)	30.4 (7.0)	32.3 (7.1)
*Participants could be under one or more categories and were counted once at each category		

**Table S2. Viral load (log10) median copies**

Illness day	Viral Load Median (Log10 viral copies/ml)		
	Placebo	mRNA-1273	Difference
1	6.7	3.4	3.4
3	3.0	0	3.0
5	2.3	0	2.3
7	0	0	0
9	0	0	0
14	0	0	0
21	0	0	0
28	0	0	0

**Table S3. Mixed model repeated measures estimates displayed in Figure 2A**

Illness Day	mRNA-1273 (n=36)			Placebo (n=595)		
	Estimate of Viral Copies (log10)	Lower Bound 95% CI	Upper Bound 95% CI	Estimate of Viral Copies (log10)	Lower Bound 95% CI	Upper Bound 95% CI
1	4.10	3.44	4.76	6.20	6.04	6.37
3	1.02	0.21	1.84	2.77	2.58	2.97
5	0.35	0	1.10	2.09	1.91	2.27
7	0.50	0	1.20	1.74	1.57	1.91
9	0.06	0	0.64	1.09	0.94	1.24
14	0.39	0	0.83	0.51	0.40	0.62
21	0.00	0	0.31	0.25	0.18	0.33
28	0.00	0	0.18	0.09	0.05	0.13

Note: Of the 48 mRNA-1273 viral copy participants, 9 did not have the day 1 illness nasopharyngeal swab available, and another 3 participants had a nasopharyngeal day 1 swab that was negative, leaving 36 for the MMRM modeling. Of the 653 mRNA-1273 viral copy participants, 43 did not have the day 1 illness nasopharyngeal swab available, and another 15 participants had a nasopharyngeal day 1 swab that was negative, leaving 595 for the MMRM modeling.

**Table S4. Viral copy reduction (log10) in mRNA-1273 compared to placebo based on the mixed model repeated measures model Figure 2B**

<b>Illness Day</b>	<b>Viral copy reduction (Log10) in mRNA-1273 compared with placebo</b>	<b>Lower Bound 95% CI</b>	<b>Upper Bound 95% CI</b>	<b>p-value</b>
1	2.10	1.42	2.78	<.0001
3	1.75	0.91	2.59	<.0001
5	1.74	0.96	2.51	<.0001
7	1.24	0.52	1.96	0.0007
9	1.03	0.43	1.63	0.0008
14	0.12	-0.34	0.58	0.0616
21	0.27	-0.06	0.59	0.1106
28	0.09	-0.10	0.27	0.3643

**Table S5. Vaccine effect on BOD and BOI**

	<b>Placebo</b>	<b>mRNA-1273</b>
	N=14164	N=14287
n (%)		
Number of participants with each level of BOD score*		
0 Without Covid-19	13394 (94.6)	14230 (99.6)
1 Covid-19 without hospitalization	741 (5.2)	55 (0.4)
2 Covid-19 with hospitalization	28 (0.2)	2 (<0.1)
3 Deaths	1 (<0.1)	0
Mean of BOD Score (SD)†	0.1 (0.24)	0 (0.07)
Treatment comparison (mRNA-1273 vs Placebo)‡		
Ratio of the mean BOD score (95% CI)		0.07 (0.05-0.09)
1 - ratio of the mean BOD score (95% CI)		93.2 (91.0-94.8)
Number of participants with each level of BOI score n (%)§		
0 No infection	13295 (93.9)	14187 (99.3)
1/2 Asymptomatic infection	99 (0.7)	43 (0.3)
1 Covid-19 without hospitalization	741 (5.2)	55 (0.4)
2 Covid-19 with hospitalization	28 (0.2)	2 (<0.1)
3 Deaths	1 (<0.1)	0
Mean of BOI Score (SD) †	0.06	0.01
Treatment comparison (mRNA-1273 vs Placebo)‡		
Ratio of the mean BOI score (95% CI)		0.088 (0.07-0.110)
1 - ratio of the mean BOI score (95% CI)		91.2 (89-93)
<p>BOD = Burden of Disease. BOI = Burden of Infection. BOD was defined based on adjudicated Covid-19 cases. *Number of participants who are without Covid-19 at randomization and have available post-baseline data. Percentages are based on number of participants with BOD score. †The maximum BOD/BOI score from randomization through study completion. ‡Vaccine efficacy is estimated using proportional means model including vaccination group as fixed effect and stratified with stratification factor at randomization. BOI was defined based on asymptomatic infections and adjudicated Covid-19 cases. BOI score of 0=No infection, 1/2=Asymptomatic infection, 1=Covid-19 without hospitalization, 2=COVID-19 with hospitalization, and 3=Death. §Number of participants who are without SARS-CoV-2 infection at baseline and have available post-baseline data. Percentages are based on number of participants with BOI score.</p>		

**Table S6. Variants classification (as of September 30, 2021)<sup>1</sup>**

Variant (PANGO)†	Spike protein substitutions	Name (Nextstrain)‡	First Detected	WHO Label	Original designations
<b>VBM</b>					
B.1.1.7	Δ69/70, Δ144, (E484K*) (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*)	20I/501Y.V1	United Kingdom	Alpha	VOC
B.1.351, B.1.351.2, B.1.351.3	D80A, D215G, Δ241/242/243, K417N, E484K, N501Y, D614G, A701V	20H/501.V2	South Africa	Beta	VOC
P.1, P.1.1, P.1.2	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I	20J/501Y.V3	Japan/Brazil	Gamma	VOC
B.1.427§	L452R, D614G	20C/S:452R	United States- (California)	Epsilon	VOC, VOI
B.1.429§	S13I, W152C, L452R, D614G	20C/S:452R	United States- (California)	Epsilon	VOC, VOI
B.1.525	A67V, 69del, 70del, 144del, E484K, D614G, Q677H, F888L	20A/S:484K	United Kingdom/Nigeria December 2020	Eta	VOI
B.1.526	L5F, (D80G*), T95I, (Y144*), (F157S*), D253G, (L452R*), (S477N*), E484K, D614G, A701V, (T859N*), (D950H*), (Q957R*)	20C/S:484K	United States (New York) – November 2020	Iota	VOI
B.1.617.1	(T95I), G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H	20A/S:154K	India – December 2020	Kappa	VOI
B.1.617.3	T19R, G142D, L452R, E484Q, D614G, P681R, D950N	20A	India – October 2020	None	VOI
B.1.621	T95I, Y144S, Y145N, R346K, E484K or the escape mutation, N501Y, D614G, P681H, and D950N.		India	Mu	VBM
P.2	E484K, D614G, and V1176F, F565L*		India	Zeta	VOI
<b>VOC</b>					
B.1.617.2, AY.1, AY.2, AY.3, AY.4, AY.5, AY.6, AY.7, AY.8, AY.9, AY.10, AY.11, AY.12	T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, D950N	21A/S:478K	India	Delta	VOC

VBM=Variant being monitored. VOC=Variant of concern. VOI=Variant of interest. \*detected in some sequences but not all. †PANGO (Phylogenetic Assignment of Named Global Outbreak) nomenclature of lineages. PANGO is a software tool developed by members of the Rambaut Lab, and associated web application was developed by the Centre for Genomic Pathogen Surveillance in South Cambridgeshire, intended to implement the dynamic nomenclature of SARS-CoV-2 lineages. Next strain nomenclature. ‡Nextstrain collaboration between researchers in Seattle, USA and Basel, Switzerland, provides open-source tools for visualizing the genetics of outbreaks with a goal to support public health surveillance by facilitating understanding of the spread and evolution of pathogens. §Initially categorized as VOC, then a VOI and currently no longer considered a VOI. Source: CDC <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern>

**Variant Being Monitored (VBM):** Variants being monitored for which there are data indicating a potential or clear impact on approved or authorized medical countermeasures or that has been associated with more severe disease or increased transmission but are no longer detected or are circulating at very low levels in the United States, and as such, do not pose a significant and imminent risk to public health in the United States.

**Variants of Interest (VOI):** A variant with specific genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, reduced efficacy of treatments, potential diagnostic impact, or predicted increase in transmissibility or disease severity.

**Variants of Concern (VOC):** A variant for which there is evidence of an increase in transmissibility, more severe disease (increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures.

**Variants of High Consequence:** A variant of high consequence has clear evidence that prevention measures or medical countermeasures (MCMs) have significantly reduced effectiveness relative to previously circulating variants.

**Table S7. Counts for select lineages**

Revised lineage	2020						2021				
	Jul	Aug	Sept	Oct	Nov	Dec	Jan	Feb	March	April	May
<b>Time-matched GISAID</b>											
B.1/B.1.2	3290	3336	2742	4468	11986	15442	27287	20756	15842	3984	580
B.1.1.7	29	37	0	1	19	136	1472	7386	44563	92057	49674
B.1.351	0	0	0	0	0	0	36	157	626	989	484
B.1.617.2	2	0	0	0	0	1	5	8	20	765	2459
B.1.427/429	4	4	18	36	375	2263	12253	14245	16612	8137	1523
B.1.525	0	0	0	0	0	1	32	86	396	498	172
P.1	0	0	0	0	0	0	10	49	1674	8586	7307
B.1.526	1	0	1	3	4	84	779	2920	13258	20514	8564
<b>Clinical study samples</b>											
B.1/B.1.2	1	15	30	61	138	194	100	8	1	0	0
B.1.1.7	0	0	0	0	0	0	0	0	2	3	0
B.1.351	0	0	0	0	0	0	0	0	1	0	0
B.1.617.2	0	0	0	0	0	0	0	0	0	0	0
B.1.427/429	0	0	0	0	1	11	18	1	0	0	1
B.1.525	0	0	0	0	0	0	0	0	0	0	0
P.1	0	0	0	0	0	0	1	0	0	0	0
B.1.526	0	0	0	0	0	0	0	0	1	1	0

**Table S8. Percentage for select lineages time-matched GISAID and clinical datasets**

Revised lineage	2020						2021				
	Jul	Aug	Sept	Oct	Nov	Dec	Jan	Feb	March	April	May
<b>Time-matched GISAID</b>											
B.1/B.1.2	98.9	98.8	99.3	99.1	96.8	86.1	65.2	45.5	17.0	2.9	0.8
B.1.1.7	0.9	1.1	0.0	0.0	0.2	0.8	3.5	16.2	47.9	67.9	70.2
B.1.351	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.7	0.7	0.7
B.1.617.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	3.5
B.1.427/429	0.1	0.1	0.7	0.8	3.0	12.6	29.3	31.2	17.9	6.0	2.2
B.1.525	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.4	0.4	0.2
P.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.8	6.3	10.3
B.1.526	0.0	0.0	0.0	0.1	0.0	0.5	1.9	6.4	14.3	15.1	12.1
<b>Clinical study samples</b>											
B.1/B.1.2	100.0	100.0	100.0	100.0	99.3	94.6	84.0	88.9	20.0	0.0	0.0
B.1.1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.0	75.0	0.0
B.1.351	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.0	0.0	0.0
B.1.617.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
B.1.427/429	0.0	0.0	0.0	0.0	0.7	5.4	15.1	11.1	0.0	0.0	100.0
B.1.525	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
P.1	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0
B.1.526	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.0	25.0	0.0

**Table S9. Summary of variants in adjudicated Covid-19 cases starting after randomization in the per-protocol set**

	Placebo	mRNA-1273
Covid-19 n (%)	N=14164	N=14287
COVID-19* cases, n (%)	769 (5.4)	56 (0.4)
Number of events by lineage, n (%)		
B.1	5 (0)	-
B.1.1	1 (0)	-
B.1.1.128	1 (0)	-
B.1.1.186	2 (0)	-
B.1.1.207	1 (0)	-
B.1.1.222	8 (0.1)	-
B.1.1.316	1 (0)	-
B.1.1.337	1 (0)	-
B.1.1.432	1 (0)	-
B.1.1.434	1 (0)	-
B.1.1.519	2 (0)	-
B.1.2	394 (2.8)	13 (0.1)
B.1.232	1 (0)	-
B.1.234	6 (0)	-
B.1.240	1 (0)	-
B.1.243	23 (0.2)	1 (0)
B.1.311	6 (0)	-
B.1.349	1 (<0.0)	-
B.1.369	2 (<0.0)	-
B.1.375	1 (<0.0)	-
B.1.382	1 (<0.0)	-
B.1.396	1 (<0.0)	-
B.1.404	2 (<0.0)	-
B.1.427	6 (<0.0)	-
B.1.429	9 (0.1)	3 (<0.0)
B.1.517	2 (<0.0)	-
B.1.526.3	1 (<0.0)	-
B.1.544	2 (<0.0)	-
B.1.551	1 (<0.0)	-
B.1.561	5 (<0.0)	-
B.1.564	3 (<0.0)	-
B.1.587	8 (0.1)	-
B.1.595	2 (<0.0)	-
B.1.596	13 (0.1)	-
B.1.599	1 (<0.0)	-
B.1.605	1 (<0.0)	-
B.1.609	1 (0)	-
NONE	20 (0.1)	-
P.1	1 (0)	-
P.2	2 (0)	-
R.1	3 (0)	-
WILD TYPE	1 (0)	-
By First Detected, n (%)		
Brazil	1 (0)	-
P.1	1 (0)	-
California	15 (0.1)	3 (0)
B.1.427	6 (0)	
B.1.429	9 (0.1)	3 (0)
Variant of Concern		
B.1.427	6 (0)	
B.1.429	9 (0.1)	3 (0)
P.1	1 (0)	
Variant of Interest		
P.2	2 (0)	

NONE=unable to assign to a lineage. \*With the censoring rules for efficacy analyses. COVID-19 case is based on eligible symptoms and positive RT-PCR within 14 days. Percentages based on adjudicated cases starting 14 days post-randomization in the per-protocol set. If a participant had a positive RT-PCR test at pre-dose 2 visit (day 29) without eligible symptoms with 14 days, or positive Elecsys at scheduled visits prior to becoming a COVID-19 case, the participant was censored at the date with positive RT-PCR or Elecsys. Table 14.2.1.1.2.1.4.1







Figure S2. Viral copy number by age groups  $\geq 18$ - $<65$  and  $\geq 65$  years

A.  $\geq 18$ - $<65$


B.  $\geq 65$



Data underlying graphs above.

Illness Day	$\geq 18$ - $<65$ years			$\geq 65$ years		
	n	Log10 viral copies		n	Log10 viral copies	
		Mean	Std Error		Mean	Std Error
Placebo						
1	514	6.20	0.09	81	6.25	0.23
3	442	2.76	0.11	63	2.87	0.31
5	440	2.10	0.10	61	2.13	0.30
7	450	1.70	0.10	64	2.02	0.27
9	411	1.09	0.08	55	1.27	0.27
14	407	0.51	0.06	62	0.49	0.16
21	398	0.26	0.04	55	0.15	0.10
28	408	0.08	0.02	66	0.15	0.09
mRNA-1273						
1	32	4.08	0.41	4	4.26	1.58
3	27	1.11	0.34	3	0.96	0.96
5	26	0.34	0.19	4	0.95	0.95
7	26	0.51	0.25	4	0.82	0.82
9	28	0.08	0.08	4	0	0
14	25	0.42	0.24	1	0	-
21	23	0.00	0.00	3	0	0
28	24	0.00	0.00	3	0	0


**Figure S3. Time to undetectable SARS-CoV-2 viral copies**



**Dotted lines represent medians (days) for placebo (7) and mRNA-1273 (4). Nasopharyngeal swab at day 1 of illness and saliva samples at days 3, 5, 7, 9, 14, 21, and 28 of illness. Lower limit of quantitation: <2.85 log<sub>10</sub> copies/ml for saliva samples**

Measure	Placebo N=595	mRNA-1273 N=36
Median	4.0	7.0
1 <sup>st</sup> quartile	5.0	3.0
3 <sup>rd</sup> quartile	7.0	7.0

Figure S4. Viral copy number CA variants



Data underlying graph above.

Illness Day	mRNA-1273			Placebo		
	n	Mean	SEM	n	Mean	SEM
1	15	7.4	0.3	2	6.0	1.0
3	14	4.3	0.6	2	3.2	0.3
5	15	3.1	0.6	2	0	0
7	15	2.1	0.5	2	0	0
9	14	1.8	0.6	2	0	0
14	14	0.4	0.2	2	0	0
21	13	0.4	0.3	2	0	0
28	15	0.2	0.2	2	0	0

SEM=standard error of the mean

## References

1. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. (Centers for Disease Control and Prevention, 2021).